Yesterday, we announced we will present clinical data from the RUBY and EdiTHAL trials of reni-cel at the European Hematology Association 2024 Congress in June. Learn more: https://bit.ly/3WBoV0T #EHA2024 #geneediting #sicklecelldisease #thalassemia
Editas Medicine
Biotechnology Research
Cambridge, Massachusetts 42,856 followers
What If You Could Repair Broken Genes?
About us
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.
- Website
-
http://www.editasmedicine.com
External link for Editas Medicine
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2013
- Specialties
- Genome Editing, In Vivo (in body) Editing, Engineered Cell Medicines, Ocular Medicines, Genetic Diseases, Blood Diseases, Sickle Cell Disease, Cancer, Rare Diseases, Immunogenetics, Transfusion-Dependent Beta Thalassemia, and Hematopoietic Stem Cells
Locations
-
Primary
Get directions
11 Hurley St
Cambridge, Massachusetts 02141, US
-
Get directions
4909 Nautilus Ct N
Suite 208/211
Boulder, Colorado 80301, US
Employees at Editas Medicine
Updates
-
#News: Editas Medicine to present clinical data from the RUBY and EdiTHAL trials of reni-cel at the European Hematology Association 2024 Congress in June. Read the press release for details: https://bit.ly/3WBoV0T #EHA2024 #geneediting #sicklecelldisease #thalassemia
-
-
Congratulations to Greg Whitehead, Editas Medicine’s new Executive Vice President and Chief Technical and Quality Officer. Greg is a valued member of the Editas team with deep expertise, experience, and passion. Congratulations, Greg!
-
-
Earlier today, we announced the presentation of preclinical data demonstrating several in vivo capabilities towards developing transformative in vivo gene editing medicines. Learn more: bit.ly/4bgVCVN #ASGCT24 #geneediting #invivo #biotechnology
-
-
We are looking forward to another day at #ASGCT24. Visit us at our poster (#1681), “Metagenomic Discovery and Screening of Novel Recombinase Proteins for Targeted Integration.” https://bit.ly/3UbVIXr. #geneediting #biotechnology
-
-
#News: Editas Medicine preclinical data highlights advancement of in vivo gene editing medicine technologies at the American Society of Gene and Cell Therapy Annual Meeting. Read the press release for details: https://bit.ly/4bgVCVN #ASGCT24 #geneediting #invivo #biotechnology
-
-
Attending #ASGCT24? Stop by our poster (#1182) today, “Chemically Modified AsCas12a Guide RNAs Improve Lipid Nanoparticle-Mediated In Vivo Gene Editing in Different Tissues,” or visit our website to view the poster: https://bit.ly/4dACVOC. #geneediting #invivo #biotechnology
-
-
Good morning from #ASGCT24! Throughout the week we are presenting pre-clinical data to support our development of transformative in vivo gene editing medicines. For presentation information, visit https://bit.ly/3UbVIXr. #geneediting #invivo #biotechnology
-
-
Earlier today, we reported business highlights and financial results for the first quarter 2024. Learn more: https://bit.ly/3yaL3VC #geneediting #biotechnology
-
-
Darshana, a patient advocate living with #thalassemia, shares how we all can support the thalassemia community today and every day. Editas is honored to recognize and support the thalassemia community on #WorldThalassemiaDay. #ThalassemiaAwareness #MentalHealth #PatientAdvocacy